Nanospheres as Vehicles for Treatment of Neuroblastoma
纳米球作为治疗神经母细胞瘤的载体
基本信息
- 批准号:6710556
- 负责人:
- 金额:$ 17.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-04-01 至 2006-09-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Neuroblastoma, the most common solid tumor of children, arises from a block of differentiation and a resultant continuation of the proliferative state. Neuroblastomas often spontaneously revert by undergoing partial differentiation, which leads to their ultimate degeneration. A useful therapeutic approach for clinical neuroblastoma may therefore encompass strategies to force differentiation.
In our ongoing studies we have developed an anti-oxidant synergistic formulation ("ASF"), comprised of alpha-tocopherol (vitamin E), sodium pyruvate and phosphatidyl choline, that supports axonal elaboration in cultured neurons. We demonstrate herein that ASF prevents neuroblastoma proliferation and promotes their differentiation in culture, even in the presence of serum (which otherwise induces rapid neuroblastoma proliferation), This holds the promise that ASF, with proper administration, may foster differentiation (and therefore ultimate degeneration) of neuroblastoma in situ and may therefore represent a novel approach towards suppression of clinical neuroblastoma. However, ASF was unable to prevent continued increase in size of tumors generated following injection of neuroblastoma into nude mice, despite injection directly into the tumor. Since ASF is effective on these cells in culture in the presence of serum, one likely interpretation is that we were unable to maintain a sufficient concentration of ASF at the tumor site. To accomplish this, we propose administration of ASF within our novel non-toxic nanospheres, which foster intracellular delivery of their contents Encapsulation within nanospheres dramatically improves the efficacy of known anti-cancer drugs, as well as that of ASF, in culture.
We propose to determine the efficacy of nanosphere-mediated delivery of ASF and known anti-cancer agents on neuroblastoma tumors in nude mice by injection into the tumor site, transdermal application (our data indicate that our nanospheres foster transdermal delivery of their contents), inclusion within their diet (our data indicate that dietary administration of ASF is physiologically effective), and combinations of these methods. Controls will include injection and transdermal application at sites distal to the tumor, administration of non-encapsulated compounds, and administration of "empty" nanospheres. Resulting data will indicate whether or not nanospheres represent useful delivery agents for cancer therapy.
描述(由申请人提供):神经母细胞瘤是儿童最常见的实体瘤,源于分化阻滞和增殖状态的持续。 神经母细胞瘤通常通过部分分化自发地恢复,这导致其最终变性。因此,临床神经母细胞瘤的一种有用的治疗方法可能包括强制分化的策略。
在我们正在进行的研究中,我们已经开发了一种抗氧化协同制剂(“ASF”),其由α-生育酚(维生素E)、丙酮酸钠和磷脂酰胆碱组成,其支持培养的神经元中的轴突加工。 我们在本文中证明,ASF防止神经母细胞瘤增殖并促进其在培养物中的分化,即使在血清(其否则诱导快速神经母细胞瘤增殖)存在下也是如此。这保证了ASF在适当施用的情况下可以原位促进神经母细胞瘤的分化(并因此最终变性),因此可以代表抑制临床神经母细胞瘤的新方法。然而,ASF不能阻止将神经母细胞瘤注射到裸鼠体内后产生的肿瘤尺寸的持续增加,尽管直接注射到肿瘤中。由于ASF在血清存在下对培养物中的这些细胞有效,一种可能的解释是我们无法在肿瘤部位维持足够浓度的ASF。 为了实现这一点,我们建议在我们的新型无毒纳米球内施用ASF,其促进其内容物的细胞内递送 纳米球内的封装显著提高了已知抗癌药物以及ASF在培养中的功效。
我们建议通过注射到肿瘤部位、透皮应用(我们的数据表明,我们的纳米球促进其内容物的透皮递送)、包含在其饮食中(我们的数据表明,ASF的饮食给药在生理上有效)以及这些方法的组合来确定纳米球介导的ASF和已知抗癌剂递送对裸鼠神经母细胞瘤肿瘤的功效。 对照将包括在肿瘤远端部位的注射和经皮施用、施用未包封的化合物和施用“空”纳米球。 所得数据将表明纳米球是否代表用于癌症治疗的有用递送剂。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A nanoemulsion of an anti-oxidant synergy formulation reduces tumor growth rate in neuroblastoma-bearing nude mice.
- DOI:10.1097/01.jnen.0000268844.82358.51
- 发表时间:2007-05
- 期刊:
- 影响因子:0
- 作者:Fonghsu Kuo;Timothy Kotyla;T. Wilson;Lydia Kifle;T. Panagiotou;I. Gruverman;J. Tagne;Thomas Shea;R. Nicolosi
- 通讯作者:Fonghsu Kuo;Timothy Kotyla;T. Wilson;Lydia Kifle;T. Panagiotou;I. Gruverman;J. Tagne;Thomas Shea;R. Nicolosi
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
THOMAS B. SHEA其他文献
THOMAS B. SHEA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('THOMAS B. SHEA', 18)}}的其他基金
Intermediate Filaments 2008 Gordon Research Conference
中间长丝 2008 年戈登研究会议
- 批准号:
7479953 - 财政年份:2008
- 资助金额:
$ 17.21万 - 项目类别:
Is S-adenosyl Methionine a Nutrition: Genetic Link in AD?
S-腺苷甲硫氨酸是一种营养:AD 中的遗传联系吗?
- 批准号:
7257368 - 财政年份:2007
- 资助金额:
$ 17.21万 - 项目类别:
Is S-adenosyl Methionine a Nutrition: Genetic Link in AD?
S-腺苷甲硫氨酸是一种营养:AD 中的遗传联系吗?
- 批准号:
7385896 - 财政年份:2007
- 资助金额:
$ 17.21万 - 项目类别:
CONCURRENT TRETINOIN AND CHEMOTHERAPY WITH OR WITHOUT ARSENIC TRIOXIDE
维生素A酸与化疗同时使用或不使用三氧化二砷
- 批准号:
7200202 - 财政年份:2004
- 资助金额:
$ 17.21万 - 项目类别:
Concurrent Tretinoin and Chemotherapy With or Without Arsenic Trioxide
联合维A酸和化疗联合或不联合三氧化二砷
- 批准号:
6980628 - 财政年份:2003
- 资助金额:
$ 17.21万 - 项目类别:
HOW DO NEURONS REPLACE VIMENTIN WITH NEUROFILAMENTS?
神经元如何用神经丝取代波形蛋白?
- 批准号:
2889447 - 财政年份:1998
- 资助金额:
$ 17.21万 - 项目类别:
HOW DO NEURONS REPLACE VIMENTIN WITH NEUROFILAMENTS?
神经元如何用神经丝取代波形蛋白?
- 批准号:
2693300 - 财政年份:1998
- 资助金额:
$ 17.21万 - 项目类别:
CALPAIN/KINASE RELATIONSHIPS IN NEURONAL INJURY AND DEGENERATION
神经元损伤和退化中钙蛋白酶/激酶的关系
- 批准号:
6098450 - 财政年份:1998
- 资助金额:
$ 17.21万 - 项目类别:
CALPAIN/KINASE RELATIONSHIPS IN NEURONAL INJURY AND DEGENERATION
神经元损伤和退化中钙蛋白酶/激酶的关系
- 批准号:
6234416 - 财政年份:1997
- 资助金额:
$ 17.21万 - 项目类别:
EXACERBATION OF AD NEUROPATHOLOGY BY ASTROGLIAL FACTORS
星形胶质细胞因素加剧 AD 神经病理学
- 批准号:
2054951 - 财政年份:1994
- 资助金额:
$ 17.21万 - 项目类别:
相似海外基金
Enhancing gamete cryoprotective properties of graphene oxide by dual functionalization with antioxidants and non-penetrating cryoprotectant molecules
通过抗氧化剂和非渗透性冷冻保护剂分子的双重功能化增强氧化石墨烯的配子冷冻保护特性
- 批准号:
24K18002 - 财政年份:2024
- 资助金额:
$ 17.21万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Bilirubin Catabolism induces Plasminogen-Activator Inhibitor 1 (PAI-1) worsening Metabolic Dysfunction
胆红素分解代谢诱导纤溶酶原激活剂抑制剂 1 (PAI-1) 恶化代谢功能障碍
- 批准号:
10750132 - 财政年份:2024
- 资助金额:
$ 17.21万 - 项目类别:
Biology the initiator: Harnessing Reactive Oxygen Species for Biocompatible Polymerization
生物学引发者:利用活性氧进行生物相容性聚合
- 批准号:
10667740 - 财政年份:2023
- 资助金额:
$ 17.21万 - 项目类别:
Developing Tools to Understand an Alternative Fate of Urate in Neurodegenerative Diseases
开发工具来了解尿酸盐在神经退行性疾病中的替代命运
- 批准号:
10668103 - 财政年份:2023
- 资助金额:
$ 17.21万 - 项目类别:
Heat therapy for the treatment of SCI-induced changes in nociceptor and mitochondrial function
热疗法治疗 SCI 引起的伤害感受器和线粒体功能变化
- 批准号:
10641385 - 财政年份:2023
- 资助金额:
$ 17.21万 - 项目类别:
Exploring regulatory mechanisms of glyoxalase-1
探索乙二醛酶-1的调控机制
- 批准号:
10646721 - 财政年份:2023
- 资助金额:
$ 17.21万 - 项目类别:
Oxidative Stress and Mitochondrial Dysfunction in Chemogenetic Heart Failure
化学遗传性心力衰竭中的氧化应激和线粒体功能障碍
- 批准号:
10643012 - 财政年份:2023
- 资助金额:
$ 17.21万 - 项目类别:
Combinatorial Neuroprotective Strategies for Preterm Brain Injury
早产儿脑损伤的组合神经保护策略
- 批准号:
10798705 - 财政年份:2023
- 资助金额:
$ 17.21万 - 项目类别: